Skip to main content

Advertisement

SpringerLink
Log in

Effects of onabotulinumtoxinA treatment on efficacy, depression, anxiety, and disability in Turkish patients with chronic migraine

  • Original Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

Chronic migraine causes a serious labour loss and disability in the society and increases the risk of depression and anxiety by negatively affecting the quality of life. The purpose of this study was to investigate the effects of onabotulinumtoxinA (BoNT-A) treatment on efficacy before and after treatment in our cases with chronic migraine as well as on depression, anxiety and disability caused by migraine. According to the International Headache Classification (ICHD-III beta version), 60 adult patients who were diagnosed with chronic migraine were included in the study. A total of 155 IU BoNT-A treatment from 31 regions was administered in accordance with the protocol of PREEMPT study. Information about the characteristics of patients’ headaches, background and family history, drugs they used was recorded. At the baseline and in the first and third month after the BoNT-A injection, VAS scores, the number of both headache days and attacks, the headache duration, the frequency of application to emergency services and the intake of both analgesics and triptans during attacks were evaluated. MIDAS, BDI and BAI were evaluated at the baseline and in the third month after the BoNT-A injection. BoNT-A injection provided a significant decrease in the number of days and severity of headaches, MIDAS disability scores and psychiatric complaints in cases with chronic migraine who did not respond to prophylactic treatments in the third month of the treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Baykan B, Ertas M, Karlı N, Uluduz D, Uygunoglu U, Ekizoglu E, Kocasoy Orhan E, Saip S, Zarifoglu M, Siva A (2015) Migraine incidence in 5 years: a population-based prospective longitudinal study in Turkey. J Headache Pain 16:103

    Article  PubMed  PubMed Central  Google Scholar 

  2. Ertaş M, Siva A, Dalkara T, Uzuner N, Dora B, Inan L, Idiman F, Sarica Y, Selçuki D, Sirin H, Oğuzhanoğlu A, Irkeç C, Ozmenoğlu M, Ozbenli T, Oztürk M, Saip S, Neyal M, Zarifoğlu M, Turkish MIDAS group (2004) Validity and reliability of the Turkish Migraine Disability Assessment (MIDAS) questionnaire. Headache 44(8):786–793

    Article  PubMed  Google Scholar 

  3. Headache Classification Committee of the International Headache Society (IHS) (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 33(9):629–808. doi:10.1177/0333102413485658

    Article  Google Scholar 

  4. Minen MT, Begasse De Dhaem O, Kroon Van Diest A, Powers S, Schwedt TJ, Lipton R, Silbersweig D (2016) Migraine and its psychiatric comorbidities. J Neurol Neurosurg Psychiatry. doi:10.1136/jnnp-2015-312233

    PubMed  Google Scholar 

  5. Boudreau GP, Grosberg BM, McAllister PJ, Lipton RB, Buse DC (2015) Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: an open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety. Int J Gen Med 18(9):79–86

    Article  Google Scholar 

  6. Ashina S, Serrano D, Lipton RB, Maizels M, Manack AN, Turkel CC, Reed ML, Buse DC (2012) Depression and risk of transformation of episodic to chronic migraine. J Headache Pain 13(8):615–624

    Article  PubMed  PubMed Central  Google Scholar 

  7. Bigal ME, Serrano D, Reed M, Lipton RB (2008) Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 71(8):559–566

    Article  PubMed  Google Scholar 

  8. Lucchesi C, Baldacci F, Cafalli M, Chico L, Lo Gerfo A, Bonuccelli U, Siciliano G, Gori S (2015) Evidences of reduced antioxidant activity in patients with chronic migraine and medication-overuse headache. Headache 55(7):984–991

    Article  PubMed  Google Scholar 

  9. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT Chronic Migraine Study Group (2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50(6):921–936

    Article  PubMed  Google Scholar 

  10. Khalil M, Zafar HW, Quarshie V, Ahmed F (2014) Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull. J Headache Pain. 1(15):54. doi:10.1186/1129-2377-15-54

    Article  Google Scholar 

  11. Lipton RB, Varon SF, Grosberg B, McAllister PJ, Freitag F, Aurora SK, Dodick DW, Silberstein SD, Diener HC, DeGryse RE, Nolan ME, Turkel CC (2011) OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology 77:1465–1472

    Article  CAS  PubMed  Google Scholar 

  12. Dirik EB (2013) The rare applications of botulinum toxin in neurology practices. Turkiye Klinikleri J Neurol Spec Top 6(4):39–45

    Google Scholar 

  13. Lipton RB, Stewart WF, Sawyer J, Edmeads JG (2001) Clinical utility of an instrument assessing migraine disability: the Migraine Disability Assessment (MIDAS) questionnaire. Headache 41(9):854–861

    Article  CAS  PubMed  Google Scholar 

  14. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561–571

    Article  CAS  PubMed  Google Scholar 

  15. Beck AT, Epstein N, Brown G, Steer RA (1988) An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 56:893–897

    Article  CAS  PubMed  Google Scholar 

  16. Ulusoy M, Sahin NH, Erkmen H (1998) Turkish version of the Beck Anxiety Inventory: psychometric properties. J Cogn Psychother 12:163–172

    Google Scholar 

  17. Binder WJ, Brin MF, Blitzer A, Pogoda JM (2000) Botulinum toxin type A (BOTOX) for treatment of migraine. Semin Cutan Med Surg 20(2):93–100

    Article  Google Scholar 

  18. Schaefer SM, Gottschalk CH, Jabbari B (2015) Treatment of chronic migraine with focus on botulinum neurotoxins. Toxins (Basel) 7:2615–2628

    Article  CAS  Google Scholar 

  19. Whitcup SM, Turkel CC, De Gryse RE, Brin MF (2014) Development of onabotulinumtoxinA for chronic migraine. Ann N Y Acad Sci 1329:67–80

    Article  CAS  PubMed  Google Scholar 

  20. Matsuka Y, Kitamura Y, Spigelman I et al (2009) Botulinumtoxin type a (150 kDa) decreases exaggerated neurotransmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction. Neuroscience 159:1422–1429

    Article  PubMed  Google Scholar 

  21. Diener HC, Dodick DW, Aurora SK et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30:804–814

    Article  CAS  PubMed  Google Scholar 

  22. Gazerani P, Staahl C, Drewes AM, Arendt-Nielsen L (2006) The effects of botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain 122:315–325

    Article  CAS  PubMed  Google Scholar 

  23. Aoki KR (2005) Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 26:785–793

    Article  CAS  PubMed  Google Scholar 

  24. Yoldas TK, Donmez H, Solak EB, Colpak AI (2008) Demographic/clinical characteristics and MIDAS Scores of 103 consecutive migraine patients. Turkish J Neurol 6:388–393

    Google Scholar 

  25. Tombul K, Balcioglu I, Ertem DH, Bingol A, Goksan B, Uluduz D (2015) Personality profiles in patients with migraine type headache. NYS 53(2):30–36

    Google Scholar 

  26. Frampton JE (2012) OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine. Drugs 72(6):825–845

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurology Department, Sakarya University Education and Research Hospital, Sakarya, Turkey

    Bekir Enes Demiryurek, Yesim Guzey Aras & Belma Dogan Gungen

  2. Algology Department, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey

    Devrimsel Harika Ertem

  3. Psychiatri Department, Abant Izzet Baysal University Psychiatri Education and Research Hospital, Bolu, Turkey

    Atilla Tekin

  4. Neurology Department, Erzurum Regional Training and Research Hospital, Erzurum, Turkey

    Mustafa Ceylan

Authors
  1. Bekir Enes Demiryurek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Devrimsel Harika Ertem
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Atilla Tekin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mustafa Ceylan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yesim Guzey Aras
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Belma Dogan Gungen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bekir Enes Demiryurek.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Demiryurek, B.E., Ertem, D.H., Tekin, A. et al. Effects of onabotulinumtoxinA treatment on efficacy, depression, anxiety, and disability in Turkish patients with chronic migraine. Neurol Sci 37, 1779–1784 (2016). https://doi.org/10.1007/s10072-016-2665-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-016-2665-z

Keywords

Search

Navigation